Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

A compound of formula (I),

• characterized in that
• R1 denotes H or C1-4-alkyl,
• R2 denotes H or C1-4-alkyl,
• R3 denotes H or methyl,
• R4 denotes H or methyl, or
• R3 and R4 together form an ethylene bridge,
• R5 is selected from the group consisting of
• H, C1-4-alkyl-, C1-4-alkyl-O—CO—, C1-4alkyl-O—CO—C1-4-alkyl,
• C1-4-alkyl-O—C1-4-alkyl-, HO—CO— and HO—CO—C1-4-alkyl-,
• R6 is selected from the group consisting of
• H, halogen, CN, N3, C1-4-alkyl- which is optionally substituted by one or more F atoms,
• HC≡C—, OH, C1-4-alkyl-O—, HO—CH2—,
• H2C═CH—CH2—O—, HC≡C—CH2—O— and —NR6.1R6.2,
• wherein,
• R6.1 denotes H, C1-4-alkyl-CO— or C1-4-alkyl-SO2—, and
• R6.2 denotes H or C1-4-alkyl-,
• R7 is selected from the group consisting of
• H, halogen, CN, N3, C1-4-alkyl- which is optionally substituted by one or more F atoms,
• HC≡C—, OH, C1-4-alkyl-O—, HO—CH2—,
• H2C═CH—CH2—O—, HC≡C—CH2—O—, —NR7.1R7.2,
• H2N—C(NH)—, H2N—C(NH)NH—, H2N—C(NH)NH—CH2—, —COOH, C1-4-alkyl-OCO—, —C1-4-alkyl-COOH, —C1-4-alkyl-COO—C1-4-alkyl, —OCH2—COOH, —OCH2—COO—C1-4-alkyl, —P(O)(OR7.3)(OR7.4), —CH2—P(O)(OR7.3)(OR7.4) and —B(OH)2,
• wherein,
• R7.1 denotes H, C1-4-alkyl-, C1-4-alkyl-CO— or C1-4-alkyl-SO2—,
• R7.2 denotes H or C1-4-alkyl-,
• R7.3, R7.4 independently from each other denote H or C1-4-alkyl,
• R8 is selected from the group consisting of
• H, halogen, CN, N3, C1-4-alkyl- which is optionally substituted by one or more F atoms,
• HC≡C—, OH, C1-4-alkyl-O—, HO—CH2—,
• H2C═CH—CH2—O—, HC≡C—CH2—O—, —NR8.1R8.2,
• H2N—C(NH)—, H2N—C(NH)NH—, H2N—C(NH)NH—CH2—, —COOH, C1-4-alkyl-OCO—, —C1-4-alkyl-COOH, —C1-4-alkyl-COO—C1-4-alkyl, —OCH2—COOH, —OCH2—COO—C1-4-alkyl, —P(O)(OR8.3)(OR8.4), —CH2—P(O)(OR8.3)(OR8.4) and —B(OH)2, or
• R8 denotes -L2-Y1-L3-Y2-L4-R8.5
• wherein,
• R8.1 denotes H, C1-4-alkyl, C1-4-alkyl-CO— or C1-4-alkyl-SO2—,
• R8.2 denotes H or C1-4-alkyl, or
• R8.1 and R8.2 together with the nitrogen atom they are attached to form a heterocycle
• Y3,
• R8.3, R8.4 independently from each other denote H or C1-4-alkyl,
• R10, R8.5 independently from each other are selected from the group consisting of
• H, halogen, CN, N3, C1-4-alkyl, HC≡C—, OH, C1-4-alkyl-O—, HO—CH2—, H2C═CH—CH2—O—, HC≡C—CH2—O—, —NR8.5.1R8.5.2
• B(OH)2, BF3−, —S(O)2OH, —O—C(C6H6)3, —C(CH2OH)3, —CH(CH2OH)2, —CH(OH)CH2OH and —N+(R8.5.3)3,
• R8.5.1 denotes H, C1-4-alkyl, C1-4-alkyl-CO— or C1-4-alkyl-SO2—,
• R8.5.2 denotes H or C1-4-alkyl, or
• R8.5.1 and R8.5.2 together with the nitrogen atom they are attached to form a heterocycle Y3,
• R8.5.3 denotes methyl or ethyl,
• R9 denotes H or methyl,
• m, n independently from each other with the proviso that (m+n)<4, denote 0, 1 or 2,
• X denotes halogen,
• L1 denotes a bond or is selected from the group consisting of
• —CH2—, —CH2—CH2—, —CH2O—, —CO—, —S—, —SO—, —SO2—, —S—CH2—, SO—CH2— and —SO2—CH2,
• L2 denotes a bond or is selected from the group consisting of —O—, —CH2—, —CH2—CH2—, —CH2—O—, —O—CH2—, —CO—, —CH2—CO—, —CO—CH2—, —S—, —SO—, —SO2— and —O—CO—,
• L3, L4, L5 independently from each other denote a bond or a linear chain of formula (m)
• —(CH2)i—[O—(CH2)g1]p1—[NH—(CH2)g2]p2—[O—(CH2)g3]p3— (m),
• wherein
• i denotes 0, 1, 2, 3 or 4,
• g1, g2, g3 independently from each other denote 2, 3 or 4,
• p1, p3 independently from each other denote 0, 1, 2, 3 or 4,
• p2 denotes 0 or 1,
• with the provisio that the linear chain is consisting of 1 to 15 moieties selected from the group consisting of —CH2—, —O— and —NH— and with the proviso that the nitrogen atom of formula (m) is not directly linked to another nitrogen atom,
• Y1 denotes a bond, Y1.1 or —NRY1.1—,
• wherein,
• RY1.1 denotes L3-H or L3-NRY1.1.1RY1.1.2,
• wherein
• RY1.1.1 is selected from among
• H, C1-4-alkyl-, C1-4-alkyl-CO— and C1-4-alkyl-SO2—,
• RY1.1.2 denotes H or C1-4-alkyl-, or
• RY1.1.1 and RY1.1.2 together with the nitrogen atom they are attached to form a heterocycle Y3,
• Y2 denotes a bond or
• is selected from a group consisting of
• Y2.1, —CO—, —NRY2.1—CO—, —CO—NRY2.1—, —Y2.1—CONRY2.1—, —Y2.1—CO— and —NRY2.1—CO—Y2.1—, with the proviso that carbonyl moieties are not directly attached to nitrogen atoms of aromatic heterocycles,
• wherein
• RY2.1 denotes -L3-H or -L3-NRY2.1.1RY2.1.2,
• RY2.1.1 is selected from among
• H, C1-4-alkyl-, C1-4-alkyl-CO— and C1-4-alkyl-SO2—,
• RY2.1.2 denotes H or C1-4-alkyl-, or
• RY2.1.1 and RY2.1.2 together with the nitrogen atom they are attached to form a heterocycle Y3,
• Y1.1, Y2.1 independently from each other denote a linker in form of a phenylene group optionally substituted by -L5R10, or
• an optionally substituted heteroaromatic or heterocyclic moiety each containing at least one nitrogen atom,
• Y3 denotes an optionally substituted 4-7-membered heterocycle containing at least one N-atom,
• and tautomers and the pharmacologically acceptable acid addition salts thereof.